Pharmacokinetics of Extended Infusion Fosfomycin in Healthy Volunteers and Critically Ill Patients

The primary objective of this study is to evaluate the **pharmacokinetics** of a novel extended infusion regimen of fosfomycin in both healthy volunteers and critically ill patients. Understanding the pharmacokinetics is clinically relevant as it provides insights into the absorption, distribution, metabolism, and excretion of the drug, which is crucial for optimizing dosing regimens and improving therapeutic outcomes in different patient populations.

The clinical trial involves **healthy volunteers** and critically ill patients, encompassing both male and female participants. The study population includes individuals from two age categories: adults and adolescents. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their health status, with no specific lifestyle considerations such as diet or physical activity mentioned. The trial does not specify any principal inclusion criteria, and the main objective of the study has not been disclosed.

The clinical trial is designed to evaluate the **pharmacokinetics** of a novel extended infusion regimen of fosfomycin in both healthy volunteers and critically ill patients. This study is structured as a Phase 3 trial, which is a critical stage in the clinical research process, aimed at confirming the efficacy and monitoring the side effects of the treatment in a larger patient population. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from June 5, 2018, to March 1, 2029, allowing for comprehensive data collection and analysis over an extended period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This is followed by multiple follow-up visits scheduled at predetermined intervals to monitor the participants' response to the treatment and to collect necessary data. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to evaluate the overall outcomes of the treatment regimen. The expected length of participant involvement varies depending on individual response and adherence to the study protocol.

Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study procedures, or any other medical or personal reasons deemed significant by the study investigators. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is a Phase 3 study, with an estimated recruitment start date of June 5, 2018, and an estimated end date of March 1, 2029. Efficacy will be assessed through a series of predefined parameters, although specific endpoints are not detailed in the available data. The trial will likely involve systematic collection and analysis of efficacy data at various timepoints throughout the study duration. The methods and tools for measuring these parameters are not specified, but they typically include validated scales, laboratory tests, or patient-reported outcomes in similar trials. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.